SJS Investment Consulting’s First Tracks Biotherapeutics TRAX Stock Holding History

SJS Investment Consulting’s Portfolio TRAX Stock Details TRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$604	Buy	+30	New	+$561	﹤0.01%	2203

Other funds holding TRAX

Financial Enhancement Group Anderson, Indiana $839M AUM 18.63% 1-Year Est. Return

Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return

Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

Mirae Asset Global Investments

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return

Adirondack Trust Company Saratoga Springs, New York $336M AUM 29.2% 1-Year Est. Return

SJS Investment Consulting's TRAX Position: Q2 2026 in Review

SJS Investment Consulting opened a new position in First Tracks Biotherapeutics (TRAX) in Q2 2026: 30 shares worth $604. The stake represents ﹤0.01% of the portfolio and ranks #2203 among its holdings.

16 funds tracked by Wall St. Rank hold TRAX as of Q2 2026.

SJS Investment Consulting held 30 shares of First Tracks Biotherapeutics worth $604 as of Q2 2026.
First Tracks Biotherapeutics was a new SJS Investment Consulting position in Q2 2026.
First Tracks Biotherapeutics made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #2203 holding.
16 funds tracked by Wall St. Rank held First Tracks Biotherapeutics as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.